• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Are we going to keep Lastacaft as our comp plan for 2013?


<











We have plenty of products to sell. Go back to your own Pharma board, dummy.

Hey Einstein..do the math stupid. 4 reps; lastacaft, restasis, lumigan, and combigan. Last I checked companies want to do more with less. Plus we are pissing the doctors off by being in their face 24-7. Its to much..they are starting to go the same way primary care went, appointment only..certain day..or better yet-closing the doors all together to industry. So you tell me is Allergan going to keep this many people doing a cluster f*ck?
 




















Similar threads